Reliability and Validity Study of the Turkish Version of the Parkinson's Disease Dyskinesia Scale (PDYS-26)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorIzmir Bakircay University
About this trial
The aim of this methodological study was to investigate the Turkish validity and reliability of the Parkinson's Disease Dyskinesia Scale (PDYS-26).The scale evaluates choreic dyskinesia.Measures the impact of dyskinesia on activities of daily living in patients with Parkinson's disease.
Hypotheses of the Study:
* Parkinson's Disease Dyskinesia Scale (PDYS-26) is reliable in Turkish. * Parkinson's Disease Dyskinesia Scale (PDYS-26) is valid in Turkish.
To determine the validity of dyskinesia;
* Tampa Kinesiophobia Scale, * Mini BesTest, * Activity Specific Balance Safety Scale (ABC) and * Parkinson's Disease Questionnaire-39 will be evaluated.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Being diagnosed with idiopathic Parkinson's disease
H&Y stage 1-3
UPDRS dyskinesia item score ≥1
Accepting to participate in the study
Disqualifiers
Diagnosis of atypical-secondary parkinsonism
Severe musculoskeletal, neurological and/or cardiopulmonary problems that may affect the results of the assessment
Mini Mental State Examination score < 24
Trial population
This study was planned as a methodological research. For this purpose, Parkinson's disease patients who applied to Izmir Çiğli Training and Research Hospital Neurology Outpatient Clinic and met the inclusion criteria will be included in the study. Written informed consent will be obtained from individuals who agree to participate in the study. Based on the commonly recommended participant-to-item ratio in validity and reliability studies (typically 5 to 10 participants per item), the sample size was determined as five times the number of items in the 26-item PDYS-26 scale, and a total of 130 patients with Parkinson's disease were included in the study.
Trial design
Design model
Case-only
Time perspective
Cross-sectional
Treatments tested in this trial
Turkish version of the Parkinson's Disease Dyskinesia Scale (PDYS-26)
Other interventionThe Turkish adaptation of the Parkinson's Disease Dyskinesia Scale (PDYS-26) is administered to individuals diagnosed with Parkinson's disease who have a dyskinesia score of ≥1 based on the Unified Parkinson's Disease Rating Scale (UPDRS) dyskinesia item. The scale is used to evaluate dyskinesia severity and assess its clinical applicability in Turkish-speaking populations.
Treatment groups
130 Participants
are divided into 1 treatment groupGroup A: Parkinson Patients with Dyskinesia1 intervention
Trial outcomes
Primary outcomes
1
(PDYS-26)
Turkish version of Parkinson's Disease Dyskinesia Scale: It is a questionnaire that assesses the impact of dyskinesia on activities of daily living. It consists of 26 items. A higher score indicates greater impact.It is considered a consistent, reliable, and valid measure. It is easy to complete and has a short administration time.
Time frame
Baseline (Day 1) and 7 days post-baseline (Day 8)Other outcomes
1
Tampa Kinesiophobia Scale
Tampa Kinesiophobia Scale: It consists of 17 items that assess avoidance of movement due to a history of injury or pain. The minimum score is 17 and the maximum score is 68; a score of 37 or above indicates a high level of kinesiophobia. A 4-point Likert scale is used to evaluate the responses (1 = strongly disagree, 2 = disagree, 3 = agree, 4 = strongly agree).
Time frame
Baseline (Day 1)2
(Mini-BesTest)
Mini BesTest Balance Scale: It is one of the clinical tests used to assess gait and balance. It consists of 4 subcomponents: anticipatory postural adjustments, reactive postural control, sensory orientation, and dynamic gait, with a total of 14 items. A higher score indicates better function.
Time frame
Baseline (Day 1)3
(ABC)
Activity Specific Balance Safety Scale: It evaluates the individual's perceived level of confidence during balance-related activities of daily living. The level of confidence is assessed by the evaluator through 16 items directly asked to the individual, with scores ranging from 0% (no confidence) to 100% (complete confidence). A total score between 0 and 49 indicates a low functional level, 50 to 80 indicates a moderate functional level, and 81 to 100 indicates a high functional level.
Time frame
Baseline (Day 1)4
(PDQ-39)
Parkinson's Disease Questionnaire-39: It is one of the most commonly used scales for assessing quality of life in individuals with Parkinson's disease. It evaluates the impact of Parkinson's disease on quality of life over the past month. Lower total scores indicate better quality of life.
Time frame
Baseline (Day 1)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov